COLL NASDAQ
Credit Risk of going bust: higher than 70% of companies Debt: 53.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.84 (down 92%), Collegium Pharmaceutical, Inc. would be worth roughly what it owes.
Total debt $857.8M against a stock market value of $748.8M.
Distance to default 3.41 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $453.9M (short-term plus half of long-term), stock volatility 44.6%; Altman Z 0.94. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Stoughton, MA 02072
US
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| SANTINI GINO | M-Exempt | 8,700 | $16.49 | 2026-06-08 |
| SANTINI GINO | M-Exempt | 8,700 | $16.49 | 2026-06-08 |
| Freund John Gordon | S-Sale | 20 | $34.05 | 2026-05-18 |
| Freund John Gordon | M-Exempt | 8,700 | $16.49 | 2026-05-15 |
| Freund John Gordon | S-Sale | 4,127 | $34.54 | 2026-05-15 |